Wuhan BravoVax Co., Ltd
Wuhan BravoVax Co., Ltd (BravoVax) is a "state level high-tech enterprise" established in the year 2012 and is specialized in the R&D, manufacturing and marketing of high-end human vaccines. BravoVax is committed to the R&D and industrialization of a number of blockbuster vaccines such as novel COVID-19 Vaccine, multivalent Rotavirus Vaccine, next-generation Pneumococcal Conjugate Vaccine, broad-spectrum Human Papillomavirus (HPV) Vaccine and Recombinant Varicella-zoster Virus (HZV) Vaccine. As one of active members in Developing Countries Vaccine Manufacturers Network (DCVMN) and a council number of China Association for Vaccines (CAV), BravoVax will gradually push these products into the market in accordance to China cGMP, WHO cGMP and IHC guidance, meeting the vaccine demands in domestic and global markets, and benefiting the whole society.
Wuhan BravoVax Co., Ltd (BravoVax) is a "state level high-tech enterprise" established in the year 2012 and is specialized in the R&D, manufacturing and marketing of high-end human vaccines. BravoVax is committed to the R&D and industrialization of a number of blockbuster vaccines such as novel COVID-19 Vaccine, multivalent Rotavirus Vaccine, next-generation Pneumococcal Conjugate Vaccine, broad-spectrum Human Papillomavirus (HPV) Vaccine and Recombinant Varicella-zoster Virus (HZV) Vaccine. As one of active members in Developing Countries Vaccine Manufacturers Network (DCVMN) and a council number of China Association for Vaccines (CAV), BravoVax will gradually push these products into the market in accordance to China cGMP, WHO cGMP and IHC guidance, meeting the vaccine demands in domestic and global markets, and benefiting the whole society.
As a high-tech company that dedicated in human vaccines and persisted in technical innovation, BravoVax has been awarded with various qualifications and honors such as “Hubei Provincial Key Laboratory for Novel Vaccine and Recombinant Protein”, “Hubei Provincial Enterprise Technology Center”, " Top 10 High-tech Gazelle Enterprise” and “China Rising Star” by Deloittee. Moreover, the project "Research and Development of Non-injectable Vaccines for Respiratory Diseases and Targeted Delivery System" led by BravoVax has officially been approved in 2022, and BravoVax became the only private company that led the project of China’s National Key R&D Program.
At present the company’s strength is its dedicated 160+ employees, making up a team with immense experience on scientific research and industrialization of quality vaccine. 85% of the employees are holding Bachelor’s degree and more than 50% of them have Master’s degree, Doctoral degree or certificate of Senior Professional. The core team members have been awarded the title “Strategic Entrepreneurial Team of Hubei Province” and have high standards of technical experience and vast practical knowledge.
The BravoVax management and technology members are from reputed National and International biopharms and institutions and are having high-end skills in various areas like research and development, manufacturing, quality management, marketing, procurement & logistics, registration and intellectual property etc. The company’s “Dream team" members have successfully triumphed various national and international GMP audits, led or participated in nearly hundred biomedical projects and acquired over 400 national and international patents.
BravoVax has five high-end technology platforms, namely bacterial fermentation, cell and virus culture, purification, formulation & quality control and are equipped with a good number of advanced instruments (like Biacore, volumetric Bioreactor, Micro-array Bioreactor, Capillary electrophoresis apparatus, Particle size analyzer, Fluorescent quantitative PCR etc). The company also has pilot production lines, which meet the R&D and manufacturing needs of high-end human vaccines and recombinant proteins. The company has established the quality management system following the cGMP pertains to key regulatory bodies like CFDA, EMA and WHO. It has key and advanced technologies in product development of Virus-like particle (VLP) preparation, polysaccharide-protein conjugation and live virus gene carrier technology along with suitable platform for large-scale cell, viral or bacterial production.
Currently a range of novel vaccines are being developed as per international standards at BravoVax. Accelerating industrialization of these projects will ensure a strong competitiveness for BravoVax in domestic and international markets. At the same time, the company is committed to improving the domestic vaccine research, development and bulk production in line with international standards. These levels of commitment, plan and execution actions of BravoVax are all in accordance to “National strategic development plan for biopharmaceutical industries”.
BravoVax is promoting its achievements in novel vaccines globally, including Asian, European and Latin American governments and also discussing and working with international companies on technology transfer of novel vaccine developments. BravoVax is not only limiting itself to domestic market, but also ready to serve to international markets in cooperation with global organizations such as DCVMN, World Health Organization (WHO), Global Alliance for Vaccines and Immunization (GAVI) and United Nations International Children's Emergency Fund (UNICEF), as well as in collaboration with other national governments for the outsourcing of vaccines. BravoVax would carry out overseas registration and global sales for the developed vaccines in accordance to the national policies and regulatory requirements on imported vaccines and eventually provide safe, effective and affordable vaccines especially to developing countries.
BravoVax believes that the completion of manufacturing facility and its extensive operations will make the company one of the high-end vaccines manufacturers and suppliers which provide high-quality vaccines as per international standards for people’s health. While achieving good economic and social benefits for itself, the company will also make immense contributions to the development of local economy and technology by promoting the technology-driven employment, domestic demand, taxation and GDP.
